Moore Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Moore Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,381	Closed	-$2.19M	–	631
2023 Q1	$2.19M	Buy	+20,381	New	+$2.35M	0.05%	238

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Moore Capital Management's RXDX Position: Q2 2023 in Review

Moore Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 20,381 shares — an estimated $2.19M sold.

Moore Capital Management first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $2.19M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Moore Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Moore Capital Management sold 20,381 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.19M.
Moore Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Moore Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $2.19M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Moore Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.